Journal: bioRxiv

Article Title: Intratumoral plasma cells mediate CD8+ T cell infiltration and successful immune checkpoint blockade therapy in de novo MPNSTs

doi: 10.64898/2026.02.18.706680

Figure Lengend Snippet: Wild-type and PC-ko mice bearing de novo MPNSTs, initiated by Nf1/Ink4a/Arf editing in the sciatic nerve, were treated daily with vehicle or CDK4/6-MEK inhibitors (palbociclib at 100 mg/kg, mirdametinib at 1 mg/kg). Mice also received 2 weekly i.p. injections of IgG control or anti-PD-L1 antibodies for the first 3 weeks of therapy. a) Time (in days) it took for MPNSTs to triple in volume. b) Waterfall plots showing percent change in tumor volume at days 10 (top) and 28 (bottom) of treatment. c) Time (in days) that tumors treated with CDK4/6 and MEK inhibitors +/- anti-PD-L1 therapy regressed, as defined by the measured tumor volume being less than volume at detection. d) Survival of wild-type (WT, top) and plasma cell-deficient (PC-ko, bottom) mice bearing MPNSTs treated with the indicated therapies. Error bars are SEM. P value was obtained via two-way ANOVA (panels a and c) or through Kaplan-Meier analysis (panel d). ns, not significant. In panels a and c, only statistically significant comparisons are shown (*, P < 0.05, **, P, < 0.01, ***, P < 0.001, ****, P < 0.0001).

Article Snippet: For the first three weeks of therapy, starting upon tumor detection, mice received IgG control (10 mg/kg anti-keyhole limpet hemocyanin [BioXCell BE009]) diluted in InVivoPure pH 7 [BioXCell IP0070]) or anti-PD-L1 (10 mg/kg anti-PD-L1 [BioXCell BE0101] diluted in InVivo Pure pH 6.5 [BioXCell IP0065]) intraperitoneally, twice per week for a total of 6 doses.

Techniques: Control, Clinical Proteomics

Journal: Cell reports

Article Title: Neutral ceramidase-dependent regulation of macrophage metabolism directs intestinal immune homeostasis and controls enteric infection

doi: 10.1016/j.celrep.2022.110560

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: CD274 (153Eu) , Fluidigm , Cat# 3153016B; RRID: AB_2687837.

Techniques: Recombinant, Western Blot, Protease Inhibitor, Enzyme-linked Immunosorbent Assay, SYBR Green Assay, Cell Culture, IP Phosphatase Assay, Software

Journal: Nature cell biology

Article Title: ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumor progression

doi: 10.1038/s41556-019-0347-9

Figure Lengend Snippet: a. Immunoblot of B cells isolated from WT (n=3), pre-lymphoma Eμ-myc (n=3) or lymphoma bearing Eμ-myc mice (n=6), lysates from different mice per group were used. b . Immunoblot from two normal human B cells (NHBC) and Burkitt’s lymphoma cell lines. c. Immunoblot from normal human colonocytes (NHC) or colon cancer cell lines. d. Immunoblot from MCF10 (non-tumorigenic breast epithelial cell line) or breast cancer cell lines. e. Pearson correlation between EIF4EBP1 and ATF4 target gene expression in Diffused Large B cell Lymphoma (DLBCL, n=562), Colorectal Adenocarcinoma (COAD, n=329), Breast Cancer (BRCA, n=1218) and Sarcoma (SARC, n=265). The center lines depict linear regression lines and shaded regions are 95% confidence intervals for regression lines. Datasets analyzed are listed in the section. Previously known ATF4 target gene list used in this analysis is shown in table. f. Kaplan-Meier plots of progression free survival (left) and overall survival (right) of DLBCL patients with high or low EIF4EBP1 expression. The survival analysis using Kaplan-Meier and two-sided log-rank test between high and low EIF4EBP1 expression groups was performed on all the patients with records of progression-free survival (left, n= 173) and overall survival (right, n=171), respectively. g. Proposed model of ATF4 and MYC co-operation in tumor progression. All immunoblots are from n=1 and unprocessed scans of blots are shown in .

Article Snippet: Normal human colonocytes were purchased from Cell Applications Inc (732Cn-10a).

Techniques: Western Blot, Isolation, Targeted Gene Expression, Expressing